Iveco Group NV (IVG) Receives a Buy from Goldman Sachs
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Costa is a 5-star analyst with an average return of 9.9% and a 62.66% success rate. Costa covers the Industrials sector, focusing on stocks such as TRATON SE, Volvo AB, and Daimler Truck Holding AG.
The word on The Street in general, suggests a Hold analyst consensus rating for Iveco Group NV with a €16.05 average price target.
Based on Iveco Group NV's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €4.56 billion and a net profit of €90 million. In comparison, last year the company earned a revenue of €4.88 billion and had a GAAP net loss of €25 million
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IVG in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
12 hours ago
- Business Insider
'Double Disaster': Boeing Stock (NYSE:BA) Slips On Strike Threat, Trouble for the F-47
Just when you think things might be going well for aerospace stock Boeing (BA), along comes the kind of thing that makes you convinced Boeing is trying to snatch defeat from the jaws of victory. A growing problem for the F-47, and the very real potential of a new strike as early as Monday, are hitting Boeing hard. Investors are reconsidering, and shares dropped nearly 2% in Thursday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. New reports suggest that the engine for the F-47 might be a while in coming. In this case, a 'while' means 'up to two years.' That alone is bad news enough for the project, because if the engine is tardy by a whopping two years, then it becomes entirely possible the whole project will be delayed until after the second Trump administration concludes. The engine was supposed to be ready in the fourth quarter of 2027. That is still a substantial time off, but now, the engine will not arrive until the second quarter of fiscal 2030. A report from Breaking Defense noted, 'Considering the aggressive timeline the Pentagon is pushing to fly the F-47 before the end of President Donald Trump's term, a next-gen engine is likely out of reach for the fighter in the near future.' But that was just the start of the F-47's problems, as another one is likely to rear its ugly head as early as Monday. The other is brewing as we speak in St. Louis, though it should be resolved well before the engine arrives. (Another) Strike Incoming Workers at three different Boeing plants in and around St. Louis may go on strike as early as Monday. Boeing made one more attempt to establish a new contract with the International Machinists and Aerospace Workers union, but that contract was pretty soundly rejected at last report. That set up the union for a week-long 'cooling-off period' that will cool off absolutely no one, and a strike is set to follow from there. So why did the union pass on the latest contracts? Reports note that the issue was not that the St. Louis plant would have received far smaller raises than their Everett equivalents under the new contract, but rather, the biggest issue is a matter of work schedules. Under the new agreement, Boeing would have been allowed to move workers from eight-hour shifts over five days to 10-hour shifts over four days. Some employees would even have been obliged to take on 12-hour shifts, but over three days. Is Boeing a Good Stock to Buy Right Now? Turning to Wall Street, analysts have a Strong Buy consensus rating on BA stock based on 18 Buys and two Holds assigned in the past three months, as indicated by the graphic below. After a 26.66% rally in its share price over the past year, the average BA price target of $256.68 per share implies 15.64% upside potential.
Business Insider
12 hours ago
- Business Insider
First Solar (FSLR) Gets a Buy from Roth MKM
Roth MKM analyst Philip Shen reiterated a Buy rating on First Solar yesterday and set a price target of $225.00. The company's shares closed yesterday at $174.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Shen covers the Technology sector, focusing on stocks such as First Solar, Array Technologies, and NEXTracker, Inc. Class A. According to TipRanks, Shen has an average return of 5.1% and a 39.57% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for First Solar with a $210.11 average price target, implying a 20.25% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $204.00 price target.
Business Insider
12 hours ago
- Business Insider
Chardan Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Chardan Capital analyst Keay Nakae maintained a Buy rating on Alnylam Pharma yesterday and set a price target of $400.00. The company's shares closed yesterday at $392.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Nakae is a 3-star analyst with an average return of 1.0% and a 38.20% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Dyne Therapeutics, and Ibio. In addition to Chardan Capital, Alnylam Pharma also received a Buy from William Blair's Myles Minter in a report issued yesterday. However, on July 17, Cantor Fitzgerald maintained a Hold rating on Alnylam Pharma (NASDAQ: ALNY). The company has a one-year high of $345.98 and a one-year low of $205.87. Currently, Alnylam Pharma has an average volume of 957.4K. Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is neutral on the stock. Most recently, in May 2025, Colleen F Reitan, a Director at ALNY bought 36.00 shares for a total of $10,362.68.
